Research outputs, reports, policy briefs and knowledge products from KIU scholars and partners.
Knowledge Outputs
Publication records can include DOI links, downloads, authors, abstracts and indexing data.
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 106-116
Prostate cancer (PCa) is characterized by pronounced molecular heterogeneity, complicating risk stratification and therapeutic decision-making. Recent advances in single-cell and spatial omics technologies enable high-resolution profiling of tumor and microen...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 88-97
Coronary artery disease (CAD) remains the leading cause of global morbidity and mortality, necessitating more effective and equitable preventive strategies. Proteogenomics-guided risk-based screening integrates genomic variation, circulating protein biomarker...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 82-87
Sickle cell disease (SCD) is a monogenic hematologic disorder that causes significant morbidity and mortality worldwide, disproportionately affecting populations of African, Indian, Middle Eastern, and Mediterranean ancestry. Whole-exome sequencing (WES) offe...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 74-81
Advances in genomic medicine have enabled the emergence of precision public health, with polygenic risk scores (PRS) offering novel tools for population-level risk stratification and intervention. Alzheimer’s disease (AD), the most prevalent neurodegenerative...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 70-73
Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality worldwide, with early detection critical to improving outcomes. Liquid biopsy genomics offers a minimally invasive approach to detect tumor-derived analytes in biofluids, provid...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 62-69
Timely and accurate detection of Mycobacterium tuberculosis (Mtb) remains a cornerstone of global tuberculosis (TB) control. Traditional diagnostic tools face limitations, including delayed results, variable sensitivity, and restricted access in resource-limi...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 53-61
Stroke remains a leading cause of mortality and disability worldwide, with both monogenic and polygenic genetic determinants contributing to individual and population risk. Population genomics provides a transformative approach to understanding these genetic...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 46-52
Familial hypercholesterolemia (FH) is a common inherited lipid disorder associated with markedly elevated cholesterol levels and a substantially increased risk of premature cardiovascular disease. Advances in population genomics, including biobank sequencing,...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 38-45
Polygenic risk scores (PRS) are increasingly used to estimate genetic susceptibility to complex diseases such as type 2 diabetes (T2D). However, most PRS models are derived from genome-wide association studies conducted primarily in European populations, rais...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 30-37
Pharmacogenomics leverages genomic information to optimize drug therapy, improving efficacy and minimizing toxicity in oncology patients. Whole-exome sequencing (WES) provides a comprehensive platform for identifying clinically actionable variants in germline...